Evidence map›Paper›PMID 37985158›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2023

[Immune Thrombocytopenia Induced by Sintilimab in Lung Cancer: 
A Case Report and Literature Review].

Jingjing Cai, Guangxia Yang, Xuemei Zhang, Linlin Liu, Mei Yan

Open access · greenAbstract readReviewCase ReportsEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jingjing CaiDepartment of Respiratory and Critical Care Medicine, Affiliated Hospital of Jining Medical University, Jining 272029, China.
Guangxia YangDepartment of Respiratory and Critical Care Medicine, Affiliated Hospital of Jining Medical University, Jining 272029, China.
Xuemei ZhangDepartment of Respiratory and Critical Care Medicine, Affiliated Hospital of Jining Medical University, Jining 272029, China.
Linlin LiuDepartment of Respiratory and Critical Care Medicine, Affiliated Hospital of Jining Medical University, Jining 272029, China.
Mei YanDepartment of Respiratory and Critical Care Medicine, Affiliated Hospital of Jining Medical University, Jining 272029, China.
Affiliated Hospital of Jining Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) show unique advantages in the treatment of lung cancer, making the treatment of lung cancer enter the era of immunotherapy, but ICIs will also have adverse reactions, and the incidence of immune-induced hematological toxicity is not very high. Immunotherapy-induced thrombocytopenia is a rare adverse event.We report one case of thrombocytopenia induced by ICIs and review the literature on thrombocytopenia associated with ICIs and discuss the clinical features, possible mechanisms, and optimal treatment. 
.

Indexed as

Lung NeoplasmsPurpura, Thrombocytopenic, IdiopathicThrombocytopeniaAntibodies, Monoclonal, HumanizedHumansAntibodies, Monoclonal, HumanizedsintilimabImmune checkpoint inhibitorsImmune-related adverse eventsImmune thrombocytopeniaLung neoplasmsSintilimab injection

Identifiers

PMID37985158
PMCPMC10600748
OpenAlexW4388869925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.